Related Experiment Videos
Inhibitors of lipoxygenase products improve survival in traumatic shock
Abstract:
We have used three selective inhibitors of arachidonic acid metabolism in order to investigate the role of lipoxygenase metabolites in the pathogenesis of traumatic shock (LD90). The following inhibitors were used: CGS-5391B (2.5 mg/kg), a cyclooxygenase and lipoxygenase inhibitor, CGS-5677 (2.0 mg/kg), a selective lipoxygenase inhibitor, and U-60,257 (0.3 mg/kg), a putative inhibitor of glutathione-s-transferase. These inhibitors did not alter arterial blood pressure or heart rate when given to sham shock rats. The traumatic shock model was characterized by a 4.5-fold increase in plasma cathepsin D activity, a 4-fold increase in plasma myocardial depressant factor (MDF) activity, and a mean survival time of 1.5 +/- 0.2 h. Only the dual inhibitor significantly blunted the accumulation of cathepsin D in the plasma (7.5 +/- 0.8 vs 11.3 +/- 0.8 U/ml, p less than 0.01). However, all three inhibitors significantly suppressed plasma MDF accumulation by 50-60%: CGS-5391B, CGS-5677, and U-60,257 (p less than 0.01). Moreover, these three agents significantly improved survival time in traumatic shock. The increased survival time and reduced MDF activity afforded by these inhibitors suggest a significant role for lipoxygenase metabolites, particularly LTC4 and LTD4, in the pathogenesis of traumatic shock.
Insights
Selective inhibitors of arachidonic acid metabolism reduced myocardial depressant factor (MDF) activity and improved survival in traumatic shock models. These findings highlight the role of lipoxygenase metabolites in shock pathogenesis.
Area of Science:
- Biochemistry
- Pharmacology
- Pathophysiology
Background:
- Traumatic shock involves complex pathophysiological processes.
- Arachidonic acid metabolism products, such as lipoxygenase metabolites, are implicated in shock.
- Understanding these pathways is crucial for developing effective treatments.
Purpose of the Study:
- To investigate the role of lipoxygenase metabolites in the pathogenesis of traumatic shock.
- To evaluate the efficacy of selective inhibitors of arachidonic acid metabolism in a traumatic shock model.
Main Methods:
- Utilized three selective inhibitors: CGS-5391B (dual cyclooxygenase and lipoxygenase inhibitor), CGS-5677 (selective lipoxygenase inhibitor), and U-60,257 (glutathione-s-transferase inhibitor).
- Administered inhibitors to rats subjected to a traumatic shock model (LD90).
- Measured plasma cathepsin D activity, myocardial depressant factor (MDF) activity, and survival time.
Main Results:
- All three inhibitors significantly suppressed plasma MDF accumulation by 50-60%.
- The dual inhibitor (CGS-5391B) significantly blunted plasma cathepsin D accumulation.
- All tested agents significantly improved survival time in rats with traumatic shock.
Conclusions:
- Lipoxygenase metabolites, particularly LTC4 and LTD4, play a significant role in the pathogenesis of traumatic shock.
- Inhibitors targeting arachidonic acid metabolism demonstrate therapeutic potential for traumatic shock.
- Reducing MDF activity is a key mechanism by which these inhibitors improve outcomes in traumatic shock.